healthi beat revenu put sale
guidanc sight
report revenu beat outlook consensu
estim reiter guidanc revenu least believ
street understand concern larg step-up least
meet guidanc vs believ near-term focu overlook
healthi long-term growth trend continu gain market share increas
payor coverag in-network cover million live diversifi
revenu biopharma partner total nearli separ began offer
proactiv screen univers vermont health network studi genet
test effect gener popul diversifi revenu
catalyst includ potenti revenu pre-announce updat
beat top-line revenu estim
street consensu estim rang test volum
quarter total y-o-i estim
manag reiter guidanc test revenu rais
revenu forecast base beat
revenu drive stock acknowledg investor concern
ramp note three factor drive perform histor season
boost volum decreas accessions-to-bil test gap sale forc
product gain new rep train summer nip launch grow
reproduct health segment view sale forc product gain primari
swing factor near-term growth
jungla weigh gross margin gross margin
forecast due bp impact jungla amort due
jungla mix shift nip trim intermediate-term gross margin
target result reduct ep estim believ investor
focus revenu growth view ep reduct materi
genom network grow vermont addit sign new
biopharma partnership total nearli disclos new
partnership univers vermont health network offer proactiv genet
screen partnership survey impact earli test popul level
take account peopl action genet mutat
look updat closur previous note publish
conclud like continu seek reimburs
hereditari cancer test lcd call manag note
expect test gain fda approv maintain coverag expect final
ncd clarifi topic fda approv
year price histori
diagnost test hereditari cancer
screen famili health plan
variou genet disord provid
predict prognost data
analyst certif import disclosur see disclosur
demand diagnost test unlik much healthcar
signific price elast use genom test
expand price sequenc declin best
posit test provid take advantag thesi base
grow economi scale commit drive
cog price lower singl price regardless breadth
genom data deliv breadth test menu
expect model result prefer access payer
relat market share gain upsid street revenu outlook
beyond
nipt test offer limit differenti account low single-
digit percentag sale
medicar reimburs ngs-base test
code unchang level outlin pama
gradual consolid hereditari cancer test market
continu industri remain highli fragment anoth
new collabor pharmaceut compani improv
test access patient suspect harbor rare diseas
addit partnership pharmaceut compani speed
adopt genom screen rare diseas popul
nipt offer meaning revenu contribut base
strength commerci channel
bolt-on acquisit acceler time-to-profit expand
propos medicar fee schedul cut reimburs ngs-
growth reproduct health non-oncolog indic
stall uptak earli adopt translat broad
genet test wide use cancer prenat care
pace adopt cardiovascular diseas immunolog
condit may slower anticip
pt base price-to-sal analysi assum multipl estim revenu million share
outstand discount back one year cost capit
risk reduct reimburs rate ngs-base genet test disrupt laboratori oper san francisco
facil result delay deliveri test result delay launch new product includ nipt neg impact revenu
growth failur fulli integr recent acquisit result reduc product lower return capit inabl
meet undisclos revenu coven relat debt facil
revenu revenu increas y-o-i estim
street consensu test volum quarter total y-o-
estim report revenu per test total
quarter due product mix grow contribut nip
patient-initi test market continu make
approxim total revenu
gross margin gross margin compar year ago
forecast cog per test prior year
acquisit intang asset jungla neg non-cash impact roughli
basi point quarter estim exclud impact jungla gross
margin miss estim basi point due mix shift
 administr expens increas includ one-tim
merger expens includ outlook estim
 sell expens increas estim
growth due higher test volum
 research spend increas vs forecast upsid
forcast primarili stock-bas comp singular includ
estim increas core spend relat higher softwar
ep net ep estim consensu
consensu
compani report oppenheim co inc estim
million except per opco estimate genet sell research profit interest incom profit loss per share continu incom loss loss per share averag common invita corp
singular disclos singular employe would grant stock-
base compens post-acquisit includ
relat stock-bas comp guid futur stock-bas
compens in-lin
gross margin estim gross margin decreas
due roughli basi point reduct jungla intang asset
balanc mix shift lower margin nip patient-initi test
estim go
respect due jungla mix shift
 increas estim
account upsid estim go
respect increas
primarili relat higher headcount relat stock-bas compens
sell market increas sell expens estim
due expect begin explor modest
direct-to-consum market pilot support patient-initi test
 ad per quarter expens account
singular quarter addit
relat time base oper mileston payment associ
transact increas project expens
total increas
ep net revis ep forecast
prior estim prior consensu increas loss
primarili associ non-cash expens singular transact
ep goe
compani report oppenheim co inc estim
genet sell research profit incom profit loss per share continu incom loss loss per share averag common analysisgross invita corp
